
Objective Nonthrombotic iliac vein lesions (NIVLs) are thought to be associated with deep vein thrombosis (DVT), yet most individuals with NIVL never develop thrombotic complications. This study assessed whether ultrasound-derived hemodynamic measurements differ between NIVL patients with and without a history of DVT, and whether these hemodynamic measurements better discriminate DVT history than percent stenosis alone. Methods We performed a retrospective case control study of patients evaluated at a tertiary academic referral center between 2022 and 2025 who underwent pelvic venous duplex ultrasound imaging. Patients with left common iliac vein (LCIV) stenoses greater than 20% were included and categorized by history of left lower-extremity DVT. Exclusion criteria included concurrent DVT or previous venous stenting. Ultrasound images were digitized to obtain vessel diameters and spectral Doppler velocities in the iliac veins. Mean velocity, peak velocity, flow rate, shear rate, and ipsilateral and contralateral ratios were calculated. Continuous variables were compared using Wilcoxon rank-sum tests, with statistical significance defined as P < .05. Results Forty-five patients were included, comprising nine patients with previous DVT, and 36 without. Among all metrics, velocity-based metrics at the compressed LCIV showed the strongest associations with a history of previous DVT, including ipsilateral velocity ratio (log2 fold change [FC], −1.539; P = .007), peak velocity (log2FC, −0.999; P = .002), and mean velocity (log2FC, −0.989; P = .002). Differences in percent stenosis were statistically significant but less discriminative than velocity-based metrics (log2FC, 0.363; P = .033). Composite metrics such as flow rate and shear rate demonstrated weaker discrimination. Dimensionality reduction analysis revealed distinct clustering based on multivariate hemodynamic features between patients with and without a history of DVT. Conclusions Among patients with NIVL, decreased velocity through the LCIV at the compression point was the strongest predictor of previous DVT, whereas percent stenosis was less discriminative. This study suggests that ultrasound-derived hemodynamic assessment can potentially provide a functional framework for risk stratification in patients with NIVL, but further prospective studies are needed to validate its clinical utility.
Objective Chronic venous insufficiency is driven primarily by venous reflux and affects nearly one-third of adults. Although superficial reflux is effectively treated with ablation, therapeutic options for deep venous reflux (DVR) remain limited. Despite decades of innovation, no prosthetic or bioprosthetic venous valve has achieved U.S. regulatory approval. We systematically reviewed device strategies, clinical and hemodynamic outcomes, complications, and barriers to translation for devices designed to treat DVR. Methods We conducted a PROSPERO-registered systematic review (CRD420251101761) of six databases from inception through February 2026, including in vivo animal and human studies evaluating prosthetic or bioprosthetic devices for DVR. Studies of native valve repair or autotransplantation were excluded. The primary outcome for human studies was clinical improvement, and secondary outcomes included patency, procedural complications, valvular function, and thrombosis. Results Of 516 records identified, 15 met inclusion criteria: eight human and seven animal studies. Two principal strategies were identified: intraluminal valve restoration and external compression, with approximately 40% of devices delivered percutaneously or endovenously. In human studies, technical success ranged from 87.7% to 100%, patency from 67% to 100%, and perioperative complication rates from 0% to 44%, consisting primarily of bleeding, wound infection, and valve thrombosis. Valve occlusion occurred in up to 28% of animal implants and 18% to 22% of select human cohorts. One perioperative death occurred in animal studies; none were reported in human studies. Among human studies, valve competency assessment methods varied substantially. Reported competency ranged from 0% to 92%, reflecting heterogeneity in imaging modalities and definitions. Discordance between anatomic patency, duplex-derived reflux reduction, and clinical improvement was frequently observed. In contemporary multicenter trial data, fewer than half of patients met predefined reflux-reduction end points despite high device patency and substantial clinical improvement, highlighting discordance between anatomic, hemodynamic, and patient-centered outcomes. By 1 year, pain had improved in up to 97% of patients; revised Venous Clinical Severity Scores decreased by 37% to 81%, with clinically meaningful (≥3-point) improvement in up to 84.6%; and ulcer healing ranged from 67% to 100%. Longer follow-up extended to 2 years in animal studies and up to 11 years in human series with various outcomes reported. Conclusions Several devices developed for DVR have demonstrated technical feasibility and symptom improvement. However, the risk of thrombosis, the marginal impact on valvular function, and the lack of standardization and selection of adequate end points in the measurement of results remain major barriers to regulatory approval. Standardized composite end points integrating objective hemodynamic measures with patient-centered outcomes are essential to advance durable DVR device development and clinical translation.
Objective The InVera Infusion Device (IVID; InVera Medical) is a novel catheter designed for the delivery of sclerosant agents during nonthermal, nontumescent ablation of incompetent superficial truncal veins of the lower extremity. This device pilot study aimed to evaluate the technical success, safety, and 12-month clinical outcome. Methods A single-center, prospective pilot study enrolled 10 patients with primary symptomatic axial reflux who underwent chemical ablation procedures with sclerosant delivery using the IVID. Primary outcomes assessed were technical procedural success, adverse events, revised Venous Clinical Severity Score (rVCSS), patient-reported outcomes based on a Heaviness, Achiness, Swelling, Throbbing, and Itching (HASTI) symptom questionnaire, and anatomical success rates from duplex ultrasound examination at baseline, 1 and 8 weeks, 3, 6, and 12 months postprocedure. Baseline and 12-month postprocedures were compared for both the rVCSS and the HASTI results using a paired t-test and a Wilcoxon signed-rank test respectively. Results Technical procedural success was 100%. There were no device-related adverse events or serious adverse events including no deep vein thrombosis recorded throughout the follow-up period. Clinician assessed rVCSS and patient reported HASTI scores both showed statistically significant reductions from baseline to 12 months (adjusted P = .03 for both). Ultrasound-based anatomical assessment at 12 months demonstrated elimination of abnormal reflux and complete or partial occlusion in 90% of patients. Conclusions The IVID provides a safe and effective technique for the delivery of sclerosant agents as part of the management of incompetent saphenous veins, demonstrating favorable 12-month anatomical, clinical and patient-reported outcomes in this pilot cohort.
Objective To compare clinical outcomes after iliac vein stenting (IVS) alone, simultaneous IVS plus ovarian vein embolization (OVE), and staged IVS followed by OVE in women with May-Thurner syndrome-associated pelvic venous disorder. Methods This single-center retrospective cohort study enrolled 184 women (aged 18-65 years) with imaging-confirmed May-Thurner syndrome and hemodynamically significant pelvic venous disorder at the Fujian Maternity and Child Health Hospital (January 2021-May 2025). The primary estimand was treatment received: IVS alone without subsequent OVE (group A, n = 71), simultaneous IVS plus OVE (group B, n = 54), or staged IVS then OVE (group C, n = 59, including 45 planned staged cases and 14 staged-after-IVS reassessment cases). The primary outcome was ≥ 50% reduction in Visual Analog Scale pain score at 12 months. Confounding was addressed using multivariable regression, propensity score matching, stabilized inverse probability of treatment weighting, overlap weighting, augmented inverse probability weighting, and repeated-measures models. OVE timing analyses were exploratory. Exact-date and time-updated OVE sensitivity analyses were performed, and available follow-up was extended through August 31, 2026. Results At 12 months, response rates were 54.9% for IVS alone, 74.1% for simultaneous IVS plus OVE, and 69.5% for staged IVS plus OVE (overall P = .059). Receipt of OVE was associated with higher adjusted odds of response compared with IVS alone [adjusted odds ratio (OR), 2.64; 95% confidence interval (CI), 1.21-5.73; P = .014], supported by inverse probability of treatment weighting (OR, 3.12; bootstrap 95% CI, 1.09-6.87). Propensity score matching (OR, 2.60; 95% CI, 0.93-7.29), overlap-weighted (OR, 2.42; 95% CI, 0.66-8.84), and augmented inverse probability weighting estimates were directionally consistent but imprecise. Planned staged and staged-after-IVS reassessment cases had 12-month response rates of 73.3% and 57.1%, respectively. Recorded 30-day events were mostly grade I; one simultaneous IVS plus OVE patient had grade IIIA coil migration requiring snare retrieval, with no sequelae. Median follow-up was 37.3 months (interquartile range, 23.7-54.2; maximum, 66.5), with 96.6% stent patency among 29 patients assessed at 60 months. Conclusions In this received-treatment analysis, adjunctive OVE was associated with higher 12-month symptom-response rates compared with IVS alone. No statistically significant difference was observed between simultaneous and staged OVE, but this exploratory timing comparison should not be interpreted as equivalence. Because residual confounding remains and OVE adds procedure-specific events, these findings support selective consideration of OVE for patients with substantial ovarian vein reflux rather than routine incorporation for all patients.
Background Venous leg ulceration (VLU) is a major cause of patient distress and health care burden. Previous studies have highlighted the importance of early endovenous ablation of superficial venous reflux to expedite healing and prevent recurrence, but the optimal venous ablation modality is unclear. Objective The aim of this study was to evaluate the effectiveness and safety of cyanoacrylate closure in patients with VLU. Design A global, prospective, single-arm observational study was conducted in 17 centers across the United States and Europe. A total of 125 participants with VLU were included and treated with the VenaSeal closure system (Medtronic), in addition to standard wound therapy, including multilayered compression. Adjuvant treatments to varicosities, perforators or the subulcer plexus were left to the discretion of treating clinicians. The primary outcome was VLU healing through 12 months. Secondary outcomes included time to ulcer recurrence, anatomic vein closure, target limb adverse events (AEs), and changes in quality-of-life (QoL) measures. Results One hundred twenty-five participants with VLU and saphenous vein reflux were enrolled. The mean ± standard deviation age was 67.9 ± 14.76 years, with 38.4% females and an overall mean body mass index of 32.4 ± 9.35. Concomitant foam sclerotherapy treatments were performed in 19.7% (31/157) of target veins. At 12 months, ulcer healing rate was 81.3%, and ulcer recurrence rate was 17.0%. The median time to ulcer healing was 92 days (95% confidence interval, 74-137). Anatomic vein closure was successful, with a closure rate of 86.6% among all treated veins through 12 months. Clinical events committee-adjudicated AE and serious AEs included: two granulomas, one hypersensitivity reaction, and four cases of phlebitis of the treated limb. Health care services used outside the index procedure yielded 0.12 adjunctive therapies per vein-year. Venous-specific and generic QoL scores showed sustained improvement compared with baseline scores. Conclusions VenaSeal effectively eliminated saphenous reflux in patients with VLU. The ulcer healing rate was high, and the recurrence rate was low. Complication rates were also low and QoL improved.